Pathogenesis and medical management of diabetic Charcot neuroarthropathy

Medical Clinics of North America

Volumn 97, Issue 5, 2013, Pages 857-872

  Mascarenhas, Janice V ^a   Jude, Edward B ^b  

^a ST JOHN'S NATIONAL ACADEMY OF HEALTH SCIENCES   (India)

^b TAMESIDE AND GLOSSOP INTEGRATED CARE NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Bisphosphonates (BPPs); Calcitonin; Charcot neuroarthropathy; Diabetic neuropathy; RANKL pathway; Total contact cast

Indexed keywords

ADALIMUMAB; ADVANCED GLYCATION END PRODUCT; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CLODRONIC ACID; DENOSUMAB; ETANERCEPT; ETIDRONIC ACID; IBANDRONIC ACID; INFLIXIMAB; MEDRONIC ACID; METHOTREXATE; NEUROPEPTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RISEDRONIC ACID; TILUDRONIC ACID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ZOLEDRONIC ACID;

ANATOMICAL VARIATION; ANKLE; ANKLE FOOT ORTHOSIS; AUTONOMIC NEUROPATHY; BREAST CANCER; CALCANEOCUBOID JOINT; CALCANEUS; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIARRHEA; DISEASE CLASSIFICATION; DRUG BIOAVAILABILITY; DRUG MECHANISM; DYSPEPSIA; ENTEROPATHY; ESOPHAGEAL IRRITATION; ESOPHAGITIS; ESOPHAGUS ULCER; FLU LIKE SYNDROME; FLUSHING; FOREFOOT; GASTROINTESTINAL SYMPTOM; HAND SWELLING; HUMAN; INJURY; INTESTINAL CRAMPING; JAW OSTEONECROSIS; JOINT; JOINT DESTRUCTION; MECHANICAL STRESS; METASTASIS; MONOTHERAPY; MULTIPLE MYELOMA; NAUSEA; NAVICULOCUNEIFORM JOINT; NEPHROTOXICITY; NEUROPATHIC JOINT DISEASE; ORTHOPEDIC CAST; ORTHOPEDIC SHOE; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; PATHOGENESIS; PES EQUINUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SENSORIMOTOR NEUROPATHY; SIDE EFFECT; SIGNAL TRANSDUCTION; SUBTALAR JOINT; SWELLING; TALONAVICULAR JOINT; TARSOMETATARSAL JOINT; URTICARIA; VOMITING; WEIGHT BEARING;

BISPHOSPHONATES (BPPS); CALCITONIN; CHARCOT NEUROARTHROPATHY; DIABETIC NEUROPATHY; RANKL PATHWAY; TOTAL CONTACT CAST;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; ARTHROPATHY, NEUROGENIC; BONE DENSITY CONSERVATION AGENTS; CALCITONIN; COMBINED MODALITY THERAPY; DEBRIDEMENT; DIABETIC FOOT; DISEASE PROGRESSION; FOOT; HEALTH BEHAVIOR; HUMANS; LIFE STYLE; PROGNOSIS; RARE DISEASES;

EID: 84883231436     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.05.002     Document Type: Review

References (64)

1. Rogers L.C., Frykberg R.G., Armstrong D.G., et al. The Charcot foot in diabetes. Diabetes Care 2011, 34:2123-2129.
2. Armstrong D.G., Todd W.F., Lavery L.A., et al. The natural history of acute Charcot's arthropathy in a diabetic foot specialty clinic. Diabet Med 1997, 14:357-363.
3. Sanders L.J., Frykberg R.G. Charcot neuroarthropathy of the foot. Levin and O'Neal's the diabetic foot 2001, Mosby, St Louis (MO), p. 439-65. 6th edition.
4. Franklin R.B., Marie B.D., Henry M.K. Hormones and disorders of mineral metabolism. Williams textbook of endocrinology 2011, Elsevier, Philadelphia, p. 1246. 12th edition.
5. Joseph A.L., Ernesto C., Lawrence G.R. Metabolic bone disease. Williams textbook of endocrinology 2011, Elsevier, Philadelphia, p. 1310. 12th edition.
6. Mangan D.F., Welch G.R., Wahl S.M. Lipopolysaccharide, tumor necrosis factor-α and IL-1β prevent programmed cell death (apoptosis) in human peripheral blood monocytes. JImmunol 1991, 146:1541-1546.
7. McConkey D.J., Hartzell P., Amador-Perez J.F., et al. Calcium-dependent killing of immature thymocytes by stimulation via the CD3/T cell receptor complex. JImmunol 1989, 143:1801-1806.
8. Jeffcoate W. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet 2005, 366:2058-2061.
9. Hofbauer L.C., Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004, 292:490-495.
10. Demer L., Abedin M. Skeleton key to vascular disease. JAm Coll Cardiol 2004, 44:1977-1979.
11. Sinha S., Munichoodappa C., Kozak G.P. Neuro-arthropathy (Charcot joints) in diabetes mellitus: a clinical study of 101 cases. Medicine (Baltimore) 1972, 51:191-210.
12. Offley S.C., Guo T.Z., Wei T., et al. Capsaicin-sensitive sensory neurons contribute to the maintenance of trabecular bone integrity. JBone Miner Res 2005, 20:257-267.
13. Collin-Osdoby P., Rothe L., Bekker S., et al. Decreased nitric oxide levels stimulate osteoclastogenesis and bone resorption both invitro and invivo on the chick chorioallantoic membrane in association with neoangiogenesis. JBone Miner Res 2000, 15:474-488.
14. Turner C.H., Pavalko F.M. Mechanotransduction and functional response of the skeleton to physical stress: the mechanisms and mechanics of bone adaptation. JOrthop Sci 1998, 3:346-355.
15. Feng Y., Tang Y., Guo J., et al. Inhibition of LPS-induced TNF-α production by calcitonin gene-related peptide (CGRP) in cultured mouse peritoneal macrophages. Life Sci 1997, 61:281-287.
16. Gough A., Abraha H., Li F., et al. Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy. Diabet Med 1997, 14:527-531.
17. Trepman E., Nihal A., Pinzur M.S. Current topics review: Charcot neuroarthropathy of the foot and ankle. Foot Ankle Int 2005, 26:46-63.
18. Pinzur M.S. Current concepts review: Charcot arthropathy of the foot and ankle. Foot Ankle Int 2007, 28:952-959.
19. Chantelau E., Onvlee G.J. Charcot foot in diabetes: farewell to the neurotrophic theory. Horm Metab Res 2006, 38:361-367.
20. Cavanagh P.R., Sims D.S., Sanders L.J. Body mass is a poor predictor of peak plantar pressure in diabetic men. Diabetes Care 1991, 14:750-755.
21. Foltz K.D., Fallat L.M., Schwartz S. Usefulness of a brief assessment battery for early detection of Charcot foot deformity in patients with diabetes. JFoot Ankle Surg 2004, 43:87-92.
22. Hofbauer L.C., Brueck C.C., Singh S.K., et al. Osteoporosis in patients with diabetes mellitus. JBone Miner Res 2007, 22:1317-1328.
23. Matricali G.A., Bammens B., Kuypers D., et al. High rate of Charcot foot attacks early after simultaneous pancreas-kidney transplantation. Transplantation 2007, 83:245-246.
24. Grant W.P., Sullivan R., Sonenshine D.E., et al. Electron microscopic investigation of the effects of diabetes mellitus on the Achilles tendon. JFoot Ankle Surg 1997, 36:272-278. [discussion: 330].
25. Kume S., Kato S., Yamagishi S., et al. Advanced glycation end-products attenuate human mesenchymal stem cells and prevent cognate differentiation into adipose tissue, cartilage, and bone. JBone Miner Res 2005, 20:1647-1658.
26. Alikhani M., Alikhani Z., Boyd C., et al. Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 2007, 40:345-353.
27. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. NEngl J Med 1998, 318:1315-1321.
28. Monnier V.M., Glomb M., Elgawish A., et al. The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution. Diabetes 1996, 45:67-72.
29. Sanders L.J., Mrdjenovich D. Anatomical patterns of bone and joint destruction in neuropathic diabetics. Diabetes 1991, 40:529A.
30. Sanders L.J., Frykberg R.G. Diabetic neuropathic osteoarthropathy: Charcot foot. The high risk foot in diabetes mellitus 1991, 297-338. Churchill Livingstone, New York. M.E. Levin, L.W. O'Neal, J.H. Bowker (Eds.).
31. Frykberg R.G., Eneroth M. Principles of conservative management. The diabetic charcot foot: principles and management 2010, 93-116. Data Trace Publishing Company, Brooklandville (MD). R.G. Frykberg (Ed.).
32. Jirkovska A.P., Kasalicky P., Boucek P., et al. Calcaneal ultrasonomentry in patients with Charcot osteoarthropathy and its relationship with densitometry in the lumbar spine and femoral neck and with markers of bone turnover. Diabet Med 2001, 18:495-500.
33. Schlossbauer T., Mioc T., Sommerey S., et al. Magnetic resonance imaging in early stage charcot arthropathy; correlation of imaging findings and clinical symptoms. Eur J Med Res 2008, 13:409-414.
34. Thomas C.C., Eichenholtz S.N. Charcot joints 1966, Springfield (IL).
35. Johnson J.E. Operative treatment of neuropathic arthropathy of the foot and ankle. JBone Joint Surg Am 1998, 80:1700-1709.
36. Armstrong D.G., Lavery L.A. Elevated peak plantar pressures in patients who have Charcot arthropathy. JBone Joint Surg Am 1998, 80:365-369.
37. Kimmerle R., Chantelau E. Weight-bearing intensity produces charcot deformity in injured neuropathic feet in diabetes. Exp Clin Endocrinol Diabetes 2007, 115:360-364.
38. Armstrong D.G., Lavery L.A. Monitoring healing of acute Charcot's arthropathy with infrared dermal thermometry. JRehabil Res Dev 1997, 34:317-321.
39. Giurini J.M. Applications and use of in-shoe orthoses in the conservative management of Charcot foot deformity. Clin Podiatr Med Surg 1994, 11:271-278.
40. Frykberg R.G., Zgonis T., Armstrong D.G., et al. Diabetic foot disorders. A clinical practice guideline (2006 revision). JFoot Ankle Surg 2006, 45:1-66.
41. Russell R.G., Watts N.B., Ebetino F.H., et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008, 19:733-759.
42. Lehenkari P.P., Kellinsalmi M., Napankangas J.P., et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002, 61:1255-1262.
43. Itzstein C., Coxon F.P., Rogers M.J. The regulation of osteoclast function and bone resorption by small GTPases. Small GTPases 2011, 2:117-130.
44. Green J.R. Bisphosphonates: preclinical review. Oncologist 2004, 9:3-13.
45. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998, 19:80-100.
46. Schweitzer D.H., Oostendorp-van de Ruit M., Van der Pluijm G., et al. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. JBone Miner Res 1995, 10:956-962.
47. Hoff A.O., Toth B.B., Altundag K., et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. JClin Oncol 2006, 24:8528.
48. Selby P.L., Young M.J., Boulton A.J. Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy?. Diabet Med 1994, 11:28-31.
49. Jude E.B., Selby P.L., Burgess J., et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia 2001, 44:2032-2037.
50. Anderson J.J., Woelffer K.E., Holtzman J.J., et al. Bisphosphonates for the treatment of Charcot neuroarthropathy. JFoot Ankle Surg 2004, 43:285-289.
51. Pitocco D., Ruotolo V., Caputo S., et al. Six-month treatment with alendronate in acute Charcot neuroarthropathy: a randomized controlled trial. Diabetes Care 2005, 28:1214-1215.
52. Zaidi M., Inzerillo A.M., Moonga B.S., et al. Forty years of calcitonin-where are we now? A tribute to the work of Iain Macintyre, FRS. Bone 2002, 30:655-663.
53. Kapurniato A., Taylor J.W. Structural and conformational requirements for human calcitonin activity. Design, synthesis and study of lactam bridge analogs. JMed Chem 1995, 38:836-847.
54. Bem R., Jirkovska A., Fejfarova V., et al. Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial. Diabetes Care 2006, 29:1392-1394.
55. Baumhauer J.F., O'Keefe R.J., Schon L.C., et al. Cytokine-induced osteoclastic bone resorption in Charcot arthropathy: an immunohistochemical study. Foot Ankle Int 2006, 27:797-800.
56. Hetland M.L., Christensen I.J., Tarp U., et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010, 62:22-32.
57. Scott D.L., Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. NEngl J Med 2006, 355:704-712.
58. Keystone E.C., Kavanaugh A.F., Sharp J.T., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.
59. van der Heijde D., Klareskog L., Rodriguez-Valverde V., et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006, 54:1063-1074.
60. Lipsky P.E., van der Heijde D.M., St Clair E.W., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. NEngl J Med 2000, 343:1594-1602.
61. Dinarello C.A. Blocking interleukin-1β in acute and chronic autoinflammatory diseases. JIntern Med 2011, 269:16-28.
62. Cohen S.B., Moreland L.W., Cush J.J., et al. Amulticentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann Rheum Dis 2004, 63:1062-1068.
63. Cohen S.B., Dore R.K., Lane N.E., et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008, 58:1299-1309.
64. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. NEngl J Med 2006, 354:821-831.